HEPCLUDEX (bulevirtide acetate-gmod)
HEPATITIS D - NTCP INHIBITOR · CHRONIC HEPATITIS D
GILEAD SCIENCES
Drug class
Hepatitis D - NTCP inhibitor
Hepatitis D – NTCP inhibitors, formally categorized by regulatory authorities as sodium taurocholate co-transporting polypeptide (NTCP)–directed hepatitis delta virus attachment or entry inhibitors, are a class of targeted antiviral agents. Read more about Hepatitis D - NTCP inhibitor
1 drugs in this class 1 manufacturers
Drugs in Hepatitis D - NTCP inhibitor
Filter & compare in the drug finder →
Opens the drug finder with Hepatitis D - NTCP inhibitor preselected. Add indication or manufacturer filters there.
Hepatitis D – NTCP inhibitors, formally categorized by regulatory authorities as sodium taurocholate co-transporting polypeptide (NTCP)–directed hepatitis delta virus attachment or entry inhibitors, are a class of targeted antiviral agents.
Represented by bulevirtide, these agents work by binding to the NTCP receptor on the surface of hepatocytes, preventing the pre-S1 domain of the viral envelope protein from docking and thereby blocking de novo viral entry into liver cells.
This therapeutic drug class is indicated specifically for the treatment of chronic hepatitis delta virus infection in adults with compensated liver disease.
-
fda.gov
Hepatitis D – NTCP inhibitors, formally categorized by regulatory authorities as sodium taurocholate co-transporting polypeptide (NTCP)–directed hepatitis delta virus attachment or entry inhibitors, are a class of targeted antiviral agents This therapeutic drug class is indicated specifically for the treatment of chronic hepatitis delta virus infection in adults with compensated liver disease
-
musechem.com
Hepatitis D – NTCP inhibitors, formally categorized by regulatory authorities as sodium taurocholate co-transporting polypeptide (NTCP)–directed hepatitis delta virus attachment or entry inhibitors, are a class of targeted antiviral agents
-
patsnap.com
Represented by bulevirtide, these agents work by binding to the NTCP receptor on the surface of hepatocytes, preventing the pre-S1 domain of the viral envelope protein from docking and thereby blocking de novo viral entry into liver cells
-
drugbank.com
Represented by bulevirtide, these agents work by binding to the NTCP receptor on the surface of hepatocytes, preventing the pre-S1 domain of the viral envelope protein from docking and thereby blocking de novo viral entry into liver cells This therapeutic drug class is indicated specifically for the treatment of chronic hepatitis delta virus infection in adults with compensated liver disease
-
dovepress.com
Represented by bulevirtide, these agents work by binding to the NTCP receptor on the surface of hepatocytes, preventing the pre-S1 domain of the viral envelope protein from docking and thereby blocking de novo viral entry into liver cells
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.